anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The project focuses on evaluating the management in the implementation of the INSPIRE respiratory health program, being applied in the health network of the municipality of Botucatu with the active co-participation of municipal managers and the local population, aiming to achieve all the proposed results. This thorough evaluation will be conducted through a longitudinal cohort study, with patient follow-up over five years. All evaluated subjects will be contacted annually to contribute to effective management and positive outcomes in respiratory health. The primary care networks (basic health and family health networks), secondary care, including urgent care and emergency units, and tertiary health care in Botucatu (tertiary hospital in the municipality of Botucatu) will participate.

The local media and primary health care unit will be informed of the monthly dates on which individuals with a history of smoking and/or passive exposure and/or respiratory symptoms can be referred for a multiprofessional evaluation. This referral can be made during a consultation or by spontaneous demand at the primary health care unit, which in turn will refer for specialized evaluation.

Statistical analyses will be divided into three main packages: disease incidence, clinical evaluation, and AI algorithms. Positive cases occurring during the evaluation period will be considered for disease incidence. For incidence calculation, the time to diagnosis for each participant will be considered in a measure expressed in person-years. Poisson regression models will be applied to estimate the relative risk for incidence among all possible groups to compare sociodemographic and other characteristics. Adjustments for possible confounding factors may be necessary and will be decided later. The second package includes the comparison between clinical characteristics and body composition. Positively and negatively screened individuals will be compared using appropriate statistical tests. Continuous variables will be tested for symmetry, and appropriate tests will be conducted (t-test or Wilcoxon; ANOVA or Mann-Whitney; parametric or non-parametric regression models). Fisher's exact tests and Chi-square (heterogeneity or trends) will be used for categorical variables.

Each participant will have their coding, preventing the identification of patients. Medical data will be kept confidential and securely stored. To ensure data quality, all researchers will be trained before the start of the study, contact with the coordinator will be allowed to clarify study protocol-related doubts, coded electronic databases will be used, which will be monitored by an external team to the study and will draw patient codes that will be monitored and their data certified. Discrepant data will automatically question the veracity of the data to reduce data inconsistency. Data will be continuously monitored to identify and correct inconsistencies. The data capture program will be REDCap, in which the developer will be solely responsible for database modifications after approval by the scientific committee.
After explaining the purpose of the study and the way it was applied to behçet's patients in the control group, Introductory Information Form, Behçet's Syndrome Activity Scale (BSAS), Richards-Campbell Sleep Questionnaire (RCSQ) will be applied.No application will be made to the control group. On the 8th day, the BSAS and RCSQ scales will be reapplied to the patients.
Embryologist fatigue surveys conducted in Spain and the United Kingdom reported that embryologists experience work-related mental health issues similar to surgeons in the United States (36.3% in Spanish and 27.8% in U.K. embryologists v. 34% in U.S. surgeons), as well as high rates of self-reported, work-related MSDs despite taking better care of themselves than the average population. Among prevalent mental issues, they highlighted fatigue, stress, and burnout as contributing factors to decreased efficiency, cynicism, and emotional exhaustion, which, together with having to handle the increasing cycle volume using conventional, manual protocols of cryomanagement, can lead to human error and IVF incidents. The known IVF incidents resulted in lost, damaged, or misplaced embryos and gametes, lawsuits, and reputational damage to patients and providers. In the absence of a "better than" cryopreservation storage solution, many programs just turned to buying more tanks and alarms and/or added expensive staff. The more effective solutions should focus on optimizing workflows by adopting innovation like automation and a digital chain of custody, organizational changes that will lead to a more productive, collaborative, and rewarding work environment, allowing embryologists to focus on patient care, scientific research, innovation, and career planning, and fewer incidents and lawsuits.

The purpose of this cross-sectional study using a web-based survey is to determine physical and mental health issues of U.S. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism, interactions with patients, attention to detail, and lead to human error, the cause of the most severe IVF incidents that often make headlines and result in costly litigation. It will also correlate how the current manual workflows contribute to these health issues, and what measures can be taken to improve both working conditions and embryologists' health, and, therefore, improve patient care.
Impaired Hepatic Function: Labetalol hydrochloride tablets should be used with caution in patients with impaired hepatic function since metabolism of the drug may be diminished.

Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers (labetalol is an alpha/beta blocker). This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery.

Jaundice or Hepatic Dysfunction :(see WARNINGS).
INTRODUCTION: Spleen tyrosine kinase (SYK), a nonreceptor tyrosine kinase, has emerged as a vital component in the complex symphony of cancer cell survival and division. SYK activation (constitutive) is documented in various B-cell malignancies, and its inhibition induces programmed cell death. In some instances, it also acts as a tumor suppressor.
AREAS COVERED: Involvement of the SYK in the cancer growth, specifically in the progression of chronic lymphocytic leukemia (CLL), diffuse large B cell lymphomas (DLBCLs), acute myeloid leukemia (AML), and multiple myeloma (MM) is discussed. Therapeutic strategies to target SYK in cancer, including investigational SYK inhibitors, combinations of SYK inhibitors with other drugs targeting therapeutically relevant targets, and recent advancements in constructing new structural assemblages as SYK inhibitors, are also covered.
EXPERT OPINION: The SYK inhibitor field is currently marred by the poor translation rate of SYK inhibitors from preclinical to clinical studies. Also, dose-limited toxicities associated with the applications of SYK inhibitors have been evidenced. Thus, the development of new SYK inhibitory structural templates is in the need of the hour. To accomplish the aforementioned, interdisciplinary teams should incessantly invest efforts to expand the size of the armory of SYK inhibitors.
This study is primarily an observational pilot study. After identifying patients as high-risk according to the following criteria: CAD and/or CVD and/or PAD and/or \>=60 years old and at least 2 of the following - renal insufficiency, diabetes, COPD, hypertension, active smoker (or active within 6 months of consent), cancer, congestive heart failure, or any blood clot - they will be asked to sign a consent form. Patients surgical and hospital course will continue as per standard of care. Prior to surgery, 8ml of blood will be collected for to assess cardiovascular biomarkers including inflammatory, metabolic, hypercoagulable and platelet biomarkers to be tested independently in Dr. Berger's lab in Smilow. Study staff will perform electrocardiograms on POD 2. Results of these ECGs will not be placed in the patients' charts. No other procedures will be done for research purposes only.
Uveal melanoma (UM) is a rare aggressive intraocular tumour that spreads most commonly to the liver in tumours with loss of one copy of chromosome 3 (HR-M3); current treatments for metastatic disease remain largely ineffective. Pre-clinical research is increasingly using three-dimensional models that better recapitulate the tumour microenvironment (TME). One aspect of the TME is the acellular extracellular matrix (ECM) that influences cell proliferation, migration and response to therapy. Although commercial matrices are used in culture, the composition and biochemical properties may not be representative of the tumour ECM in vivo. This study identifies UM metastatic risk specific ECM proteins by developing methodology for decellularisation of low- and high- metastatic risk tissue samples (LR-D3 vs. HR-M3). Proteomic analysis revealed a matrisome signature of 34 core ECM and ECM-associated proteins upregulated in HR-M3 UM. Combining additional UM secretome and whole cell iTRAQ proteomic datasets revealed enriched GO and KEGG pathways including 'regulating ECM binding' and 'PI3K/Akt signalling'. Structural analyses of decellularised matrices revealed microarchitecture of differing fibre density and expression differences in collagen 4, collagen 6A1 and nidogen 1, between metastatic risk groups. This approach is a powerful tool for the generation of ECM matrices relevant to high metastatic risk UM.
The present invention relates to a system and method for simultaneous generation of electronic medical records for artificial intelligence-enabled dynamic image recognition. The system of the present invention can be used to identify specific objects in dynamic images produced by medical equipment when performing medical clinical examinations such as ultrasound and endoscopy. Positioning and marking information for the identified object can be generated automatically. The examiner can control the system by voice commands to confirm whether the positioning and marking information of the object are correct or not. The system can automatically generate the corresponding standard output format simultaneously. At the end of the clinical examination, the system compiles relevant data and automatically and simultaneously produces an electronic medical record in complete format for the examination. The electronic medical record has an editing, adjustment and confirmation completion interface so that the examiner can modify or directly confirm the completion of the medical record output.
Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
This study is designed to test the effectiveness of the smoking cessation intervention "Sit to Quit" through a randomized-control trial. This study will compare abstinence outcomes in the Sit to Quit study group to a control group using the North Carolina State Tobacco Quit Line. This is an investigational study (n=60) designed to test Sit to Quit (STQ) versus Quit Line (QL) through a pilot randomized control trial. The proposed study is designed with double-blind procedures (participants and study staff) for randomization of 60 participants recruited through Duke Smoking Cessation Program into two groups: STQ and QL. STQ participants will receive access to the STQ Instructional Video, the STQ manual, and proactive Quit Coach calls supporting STQ. QL participants will be instructed to contact the NC Quit Line and will receive access to "web Coach" (Alere Well-being site), the Quit Line manual, and proactive Quit Coach calls supporting "Quit for Life." All statistical analysis will be performed under the directions of the statistician designated in key personnel. Outcomes of variables including: demographic variables, evaluation responses, and abstinence rates will be analyzed using general regression models using an ANOVA-based design. The study Principal Investigator Dr. James Davis will ultimately be responsible for data and safety monitoring. Subject data will be collected during visits and captured in the Electronic Medical Record. Data will be collected by phone, and this data will be stored in REDCap. Participants that experience events related to their clinical treatment will be recommended to follow-up with their provider.
Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
PROBLEM TO BE SOLVED: To efficiently obtain a pranlukast-containing granulate having narrow particle size distribution and good fluidity by modifying the surface of pranlukast having strong adhering aggregation. SOLUTION: The objective granulates contains (A) 30-90wt.% pranlukast, (B) saccharides such as lactose or mannitol in an amount of 10-100 pts.wt. based on 100 pts.wt. pranlukast, (C) a water-soluble polymer in an amount of 1-30 pts.wt. based on 100 pts.wt. pranlukast and/or (D) a surfactant such as polysorvate in an amount of 0.5-2.5 pts.wt. based on 100 pts.wt. pranlukast as active ingredients, and is obtained by granulating these active ingredients by spray drying method. The particle diameter of granulates can be controlled by changing spray-drying conditions and formed into 20-1000μm diameter. Granulates having good disintegration and dispersibility are obtained without any problem even if it is used for continuous production of packing of capsule, tabletting, etc.
The utility model discloses a magnetic health care band which comprises a nylon fiber band (3), a magnetic block (4), a magnetic plate (5), Chinese medicinal herb powder, cotton spandex band (2), a suspend (6), a hook (1). The utility model is characterized in that: a line of nylon fiber capsule grains with magnetic plate and medicinal herb powder within are set on the central line of the external surface of the nylon fiber. Nylon fiber capsule blocks of 2 to 5 lines and 2 to 7 rows are set at the left and right side of the capsules. The nylon fiber capsules contain magnetic plate and medicinal herb powder. The magnetic polarity direction of adjacent capsule bag and capsule grains are N to S opposite. The grains and the capsule blocks are set with through holes. The utility model has the functions of nourishing Yin and strengthening Yang, nourishing the kidney, activating the blood, making the heart stronger, obtaining healthier bones and tendons. Compared with prior art, the utility model has much more prominent health care function, and is easy to manufacture and apply.
Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
PURPOSE:The titled capsule having improved light stability, obtained by coating an inner solution comprising three components of nifedipine, a specific polyalkylene glycol and polyvinyl pyrrolidone, and a colorant to absorb light rays in a specific wavelength range with skin of capsuling agent. CONSTITUTION:An inner solution comprising at least three components of 1pt.wt. nifedipine, 10-50pts.wt. polyalkylene glycol (e.g., polyethylene glycol 300) having 200-600 average molecular weight, and 0.1-5pts.wt. polyvinyl pyrrolidone, and a colorant (e.g., red 102) to absorb light rays having 230-550nm wavelength range is coated with skin of capsuling agent containing dye and/or opacifying agent (e.g., titanium dioxide) to give soft capsule of nifedipine. Nifedipine is easily decomposed optically, but decomposition of nifedipine by light can be effectively decomposed by adding the colorant to the inner solution itself.
Urinary DNA representative of the tumour genome provide a promising resource as a liquid biopsy for non-invasive genomic profiling of urothelial bladder cancers. Voided urine samples will be collected prior to cystoscopy. Cell free DNA and cellular DNA will both be extracted and analyzed. A blood sample will be taken. In patients with bladder wall findings suspicious of cancer, a bladder wall biopsy will be taken and submitted for histopathology examination, according to clinical standard practice. Next generation sequencing will be applied and hotspots mutations in DNA from urine, blood and tumor. Logistic regression was used to analyze the association between predictor variables and bladder cancer. The investigators will confirm a couple of common mutations occured in urine-DNA and blood-derived DNA simultaneously and verify the specificity and sensitivity of individual variance or mutation combinations to establish an predictive model with optimal robustness in diagnosis of bladder cancer. Moreover, external consistency test will be performed on subsequent patients collection.
PURPOSE:To efficiently control permeation capacity when the titled membrane is used for permeation by bringing the soln. of a lipidic bimolecular membrane- forming substance in an org. solvent and water into contact with both surfaces of a hydrophilic polymer porous membrane, and forming a lipidic bimolecular membrane in the fine pore of the porous membrane. CONSTITUTION:A U-shaped glass vessel is bisected at the central part of the bottom part, a hydrophilic polymer porous membrane is put between the O rings provided on both end faces, an org. solvent soln. and water are respectively charged in the glass vessels on both sides, and the soln. and the water are brought into contact with each other from both sides of the membrane. When the soln. of a lipidic bimolecular membrane-forming substance in an org. solvent and the water are permeated through the membrane from both sides, an interface between the org. solvent and the water is formed in the fine pore of the porous membrane, and the lipidic bimolecular membrane is oriented at the interface. The treatment is generally carried out at about 60-80 deg.C.
Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract.

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems.

Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 cycles, after 4 cycles of treatment, and after completion of treatment (before surgery). Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
One of the most underdiagnosed and undertreated non-motor symptoms of Parkinson's Disease is chronic pain. This is generally treated with analgesics which is not always effective and can cause several side-effects. Therefore, new ways to reduce chronic pain are needed. Several experimental studies show that CT-optimal touch can reduce acute pain. However, little is known about the effect of CT-optimal touch on chronic pain. The aim of the current study is to investigate whether CT-optimal touch can reduce the chronic pain experience in Parkinson patients. In this intervention study, 17 Parkinson patients underwent three conditions; no touch, CT-optimal touch and CT non-optimal touch with a duration of one week each. During each touch week, participants received touch from their partners twice a day for 15 minutes. Results show that both types of touch ameliorate the chronic pain experience. Furthermore, it appears that it is slightly more beneficial to apply CT-optimal touch also because it is perceived as more pleasant. Therefore, we argue that CT-optimal touch might be used when immediate pain relief is needed. Importantly, this study shows that CT-optimal touch can reduce chronic pain in Parkinson's Disease and can be administered by a partner which makes it feasible to implement CT-optimal touch as daily routine.
Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.